Last reviewed · How we verify

NCT03526042

Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis

Status unknown NA Last updated 16 May 2018
What this trial tests

NA trial testing Losartan in Atherosclerosis in 40 participants. Status unknown.

Timeline
10 September 2017
Primary endpoint
31 July 2019
31 October 2019

Quick facts

Lead sponsorInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment40
Start date10 September 2017
Primary completion31 July 2019
Estimated completion31 October 2019
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran — full company profile →

Who can join

Adults 16 to 50, any sex, with Atherosclerosis or Lupus Nephritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Antibodies directed against angiotensin-II receptor (AT1-Ab) are agonist antibodies previously studied in human diseases such as preeclampsia, transplantation and scleroderma. They act by binding to the AT1 receptor and their effects can be blocked with the use of angiotensin receptor blockers (ARB). In this randomized open clinical trial the investigators will study the effect of the blockade of AT1-Ab with losartan in carotid intima-media thickness progression in patients with lupus nephritis compared to patients treated with enalapril.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Losartan

Trials testing the same drug.

Other recruiting trials for Atherosclerosis

Currently open trials in the same condition.

Other Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03526042.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing